According to our new research study on “Europe Biosimilars Market Size and Forecast to 2030 – COVID-19 Impact and Country Analysis – by Disease Indication, Route of Administration, Drug Class, and Distribution Channel,” the market is expected to grow from US$ 10,344.86 million in 2022 to US$ 1,15,125.91 million by 2030; it is estimated to record a CAGR 35.1% during 2022–2030. Factors like the increasing prevalence of chronic diseases and rising approvals of biosimilars are driving the Europe biosimilars market size and growth. 

Biosimilars introduce competition and increase the affordability of biologics, which ultimately deliver savings and value-added services to support patient care and the healthcare community. Healthcare professionals can treat more patients with high-quality biologics while reducing spending. For example, in Germany, according to Sandoz, the number of daily therapeutic doses of an anti-TNF medicine increased by 29% (from 17.18 to 22.18 million) after introducing biosimilars in 2022.

Germany has achieved acceptance of biosimilars with payers, providers, and patients as an integral part of appropriate medicine use. There is full reimbursement from a price set by the company, including immediate patient access to biosimilars. The structure of hospital tendering by multiple buying groups and separate hospital chains allows for competition among manufacturers to be maintained in Germany. For instance, in November 2018, the German Health Ministry introduced a draft bill on safety in the supply of pharmaceuticals. The Gesetz für Mehr Sicherheit in der Arzneimittelversor-gung (GSAV) bill aims to provide a legal framework for the automatic substitution of biosimilars by pharmacists in Germany.

Due to the huge potential for cost savings, the German Health Ministry introduced a new law to increase the adoption of biosimilars. As few European Union (EU) countries allow pharmacist substitution of biosimilars, this would represent a significant change in practice, particularly for Germany. Additionally, in Germany, a law passed in 2019 foresees the automatic substitution of biosimilars in pharmacies beginning in 2022, provided the Federal Joint Committee (the highest decision-making body of the self-governance of health insurers and providers) has determined the interchangeability of the medicines in question, and the prescribing physician has not explicitly excluded it. Therefore, with the growing government initiatives for adopting biosimilars in Germany, the market is expected to grow.

A biosimilar is a biological medicinal product that contains a version of the active substance of an already authorized original biological medicinal product. Biosimilars are among the UK National Health Service's (NHS) most essential medicines. The UK has been at the forefront of biosimilar adoption. According to The State of Musculoskeletal Health 2021, over 430,000 people have rheumatoid arthritis in the UK. Rheumatoid arthritis is an autoimmune disease, a long-term condition that causes pain, swelling, and stiffness in the joints. However, the Rheumatoid Arthritis Support Network suggests that a person suffering from RA who does not manage the condition well may have a lifespan of 10–15 years less than average, although it depends significantly on the severity of the disease as well as any accompanying conditions. According to the latest statistics from a 2020 study conducted by the National Institute for Health and Care Excellence (NICE), ~1% of the UK population has confirmed cases of rheumatoid arthritis.

Additionally, the study carried out by NICE says, "The incidence of the condition is ~1.5% in men and 3.6% in women developing RA per 10,000 people per year in the UK" (NICE). As with many autoimmune diseases and for unclear reasons, RA is 2–4 times more prevalent in women than men. Thus, with the growing prevalence of rheumatoid arthritis in the UK, the biosimilars market is expected to grow.

Intelerad Medical Systems Incorporated, Nuance Communications Inc, GE HealthCare Technologies Inc, Medtronic Plc, Canon Medical Systems Corp, Koninklijke Philips NV, Siemens AG, Aetna Inc, bioAffinity Technologies, Inc., LungLife AI, Inc., and Lung Screen Australia Pty Ltd are among the prominent players in global Europe biosimilars market. Leading players adopt strategies such as the launch of new products, expansion and diversification of their market presence, and expansion of new customer base for tapping prevailing business opportunities.

The report segments Europe Biosimilars market as follows: 

The Europe biosimilars market is segmented on the basis of  disease indication, route of administration, and end user. Based on disease indication, the Europe biosimilars market is segregated as cancer, diabetes, autoimmune diseases, and other disease indication. The cancer segment held the largest share of the market in 2022 and the same segment is anticipated to register the highest CAGR in the market during the forecast period. Based on route of administration, the Europe biosimilars market is segregated as intravenous, subcutaneous, and others. The intravenous segment accounted largest market share in 2022 and the same segment is expected to grow at the highest CAGR during the forecast period. The Europe biosimilars market, based on end user, is segregated as hospitals, diagnostic centers, and others. The hospitals segment held the largest share of the Europe biosimilars market in 2022.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com